Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Klink

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
JAMA Oncology|May 17, 2019
Real-world Evidence-What Does It Really Mean?Chadi Nabhan, Andrew Klink, Vinay Prasad
Journal of Comparative Effectiveness Research|January 27, 2026
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisGordon Lam, Hanke Zheng, Andrew Klink, et al.
Journal of Comparative Effectiveness Research|November 18, 2024
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisAlexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, et al.
Journal of Comparative Effectiveness Research|March 12, 2026
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano studyRichard Scott Swain, Andrew Klink, Parisa Asgarisabet, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
JAMA Oncology|May 17, 2019
Real-world Evidence-What Does It Really Mean?Chadi Nabhan, Andrew Klink, Vinay Prasad
Journal of Comparative Effectiveness Research|January 27, 2026
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisGordon Lam, Hanke Zheng, Andrew Klink, et al.
Journal of Comparative Effectiveness Research|November 18, 2024
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisAlexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, et al.
Journal of Comparative Effectiveness Research|March 12, 2026
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano studyRichard Scott Swain, Andrew Klink, Parisa Asgarisabet, et al.
Pageof 1